The WHO’s Covaxin Clearance has been postponed again due to technical difficulties, according to reliable sources.
The emergency use authorization (EUA) for Covaxin, the Indian Covid vaccine, has been delayed because the vaccine’s manufacturer, Bharat Biotech, has not responded to additional technical questions from the WHO. This will have a particular impact on students’ plans to travel abroad.
Most countries will not accept Covaxin as a vaccine unless EUA is added. Bharat Biotech claims to have submitted all necessary data for clearance. The WHO has been contacted about this.
Despite the Union Health Ministry’s predictions that global approval would be forthcoming, there is evidence that it will take longer than expected.
It is preferable to attend school in Canada while remaining in India.
“To get documents approved, a specific procedure must be followed. Covaxin’s emergency use authorization is expected to be approved by the WHO soon.” According to ANI, medical expert and Minister of State for Health Bharati Pravin Pawar made the remarks on Friday.
According to Dr. VK Paul, chair of the National Expert Group on Vaccine Administration, WHO approval of Covaxin is expected by the end of the month.
According to Bharat Biotech, Covaxin had a 77 percent efficacy rate in Phase III clinical trials.
In January, India launched a massive nationwide immunization campaign against COVID-19, with the first vaccines used being Covaxin and Covishield. Some countries, such as Russia, have recently increased their arsenals, such as the Sputnik satellite.
